Novel non-steroidal CYP17 inhibitor. reducing androgen synthesis for treatment of castration-resistant prostate cancer

Antioxidant, inhibiting free radical oxidation of biomembrane lipids, modulating the activity of membrane-bound enzymes and the receptor complexes of the brain membranes

Novel Potent and Selective Inhibitor of Protein Arginine Methyltransferase 4 (PRMT4)

Novel PRMT inhibitor, preventing arginine methylation of cellular proteins, being essentially inactive against the lysine methyltransferase SET7/9

5-FU derivative, with various anticancer agents against human cancer xenografts

Novel corticotropin-release factor 1 antagonist

Novel peptide endomorphin (EM) degradation blocker

Novel peptide endomorphin (EM) degradation blocker

Novel peptide endomorphin (EM) degradation blocker

Non-peptide angiotensin II receptor antagonist

PDE 3 inhibitor

Novel potent and highly selective c-Met inhibitor

Novel potent antitumor agent, inducing apoptosis in a panel of tumor cell lines

High affinity ligand for estrogen receptor-

Novel BCL-2 inhibitor, neutralizing the antiapoptotic activity of overexpressed BCL-2 toward staurosporine and sensitizing BCL-2-expressing cells from leukemic patients to the killing effects of staurosporine, chlorambucil, and fludarabine

Eukaryotic Ribosomal Selective Glycoside (ERSG), inducing read-through of premature stop codons (PSCs) and resulting in translation of full-length protein

Novel highly potent, selective, and CNS-penetrant inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme

Novel γ-secretase inhibitor

Oleoylethanolamide-modelled PPAR

Novel ligand of the apelin receptor (APJ), possessing high affinity for APJ (Ki 4.6 nM) and producing cardiorenal effects in vivo similar to those of ELA

Novel inhibitor of Aurora B kinase

Novel etomidate analogue, enhancing GABA A receptors currents with a concentration for 50% of maximal effect (EC 50 ) of 0.98 {plus minus} 0.02 μM, which was about three times more potent than etomidate (3.07 {plus minus} 1.67 μM), retaining the favorable

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

Novel Cell-active Inhibitor of the Undrugged Oncogenic PTP4A3 Phosphatase

Novel anti-bacterial agent, targeting the MmpL3 transporter in Mycobacterium abscessus

Novel RNA-competitive, ATP-uncompetitive eIF4A Inhibitor, decreasing BJAB Burkitt lymphoma cell viability, engaging a novel pocket in the RNA groove of eIF4A and inhibiting unwinding activity by interfering with proper RNA binding and suppressing ATP hydr

Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity

Novel water-soluble analog of progesterone

Novel Mirk kinase inhibitor, inhibiting DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites, blocking the in vivo growth of pancreatic cancer cells

Potent and bio-stable inhibitor of the chicken sEH (chxEH)